# To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

> **NCT03514901** · PHASE2 · UNKNOWN · sponsor: **Intergruppo Melanoma Italiano** · enrollment: 120 (actual)

## Conditions studied

- Melanoma Metastatic
- BRAF V600 Mutation

## Interventions

- **OTHER:** Experimental combination beyond Focal Progression
- **DRUG:** Pembrolizumab or Nivolumab

## Key facts

- **NCT ID:** NCT03514901
- **Lead sponsor:** Intergruppo Melanoma Italiano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-18
- **Primary completion:** 2023-04-29
- **Final completion:** 2023-04-29
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03514901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03514901, "To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03514901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*